6533b7dcfe1ef96bd1271fc6
RESEARCH PRODUCT
Prognostic value of troponin I in atrial fibrillation
Ricardo Rubini-puigB Quesada-oceteCarl J. LavieRicardo Rubini-costaLucas López-valeroVictor Palanca-gilFernando De La Guía-galipiensoJavier Jiménez BelloFabian Sanchis-gomarGiuseppe LippiAngeles Férez-martíGoitzane Marcaida-benitoVictor Del Moral-rondaJavier Quesada-oceteAurelio Quesadasubject
Malemedicine.medical_specialtyTime FactorsHeart failureComorbidity030204 cardiovascular system & hematologyRisk Assessment03 medical and health sciences0302 clinical medicinePredictive Value of TestsRisk FactorsInternal medicineTroponin ImedicineClinical endpointAtrial fibrillation Emergency Heart failure Mortality TroponinsTroponinsHumans030212 general & internal medicineRisk factorMortalityAdverse effectAgedRetrospective StudiesAged 80 and overbiologybusiness.industryTroponin IAtrial fibrillationMiddle AgedPrognosismedicine.diseaseTroponinAtrial fibrillationQuartileHeart failureEmergencybiology.proteinFemaleEmergency Service HospitalCardiology and Cardiovascular MedicinebusinessBiomarkersdescription
To evaluate whether circulating cardiac troponin I (cTnI) levels are associated with worst outcomes in patients with atrial fibrillation (AF).Consecutive patients visiting the emergency room (ER) with a new episode of a previously diagnosed AF or a new diagnosis of AF during ER admission between January 1st, 2010 and December 31st, 2015, were enrolled in the study (n = 2617). After applying exclusion criteria and eliminating repeated episodes, 2013 patients were finally included. Of these, 1080 patients with at least one cTnI measurement in the ER were selected and classified into 4 groups according to cTnI quartiles: Q1 (n = 147) cTnI10 ng/L (Group 1); Q2 (n = 254): 10-19 ng/L (Group 2); Q3 (n = 409): 20-40 ng/L (Group 3); and Q4 (n = 270): cTnI40 ng/L (Group 4). The median follow-up period was 47.8 ± 32.8 months. The primary endpoint was all-cause death during the follow-up.A higher mortality was found in group 4 compared with the other groups (58.9% vs. 28.5%, respectively, p 0.001), along with, hospitalizations (40.4% vs. 30.7%, p = 0.004), and readmissions due to decompensated heart failure (26.7% vs. 2.5%, p = 0.002). The probability of survival without AF recurrences was lower in the Q4 (p = 0.045). Moreover, cTnI levels40 ng/L (Q4) were an independent risk factor of death (HR, 2.03; 95% CI, 1.64-2.51; p 0.001).The assessment of cTnI at ER admission could be a useful strategy for risk stratification of patients diagnosed with AF by identifying a subgroup with medium-term to long-term increased risk of adverse events and mortality.
year | journal | country | edition | language |
---|---|---|---|---|
2021-07-01 |